Emerging Indications for Radiation in Poly-Metastatic Cancers
This activity focuses on new and emerging indications for radiation in patients with metastatic cancers.
Category
  • Immunotherapy
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Certificate of Attendance
Cost $149.00
The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients?
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons.
Category
  • Oligometastatic
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
ROBIN Oligometastasis (OligoMET) Center: Using Biomarker Correlates from a Prostate Cancer Clinical Trial to Improve Future Outcomes
Metastasis is the final common lethal pathway for most cancer patient's demise and once cancer has metastasized, it was generally considered incurable.
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased.
Category
  • Head and Neck
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages